US biotechs feel the pressure on data exclusivity
This article was originally published in Scrip
Executive Summary
Should biotech firms abandon hope of securing a 12-14-year data exclusivity period in the forthcoming US biosimilars legislation? Certainly things don't seem to be going their way after President Barack Obama came out in favour of a compromise seven-year term, citing the recent Federal Trade Commission report that dismissed the need for anything like 14 years of protection.